Endra Life Sciences INC

ENDRA Life Sciences announced a merger with Noble Africa, pivoting from its medical imaging technology to focus on Renergen's helium project, with a concurrent $50 million private placement.

ENDRA Life Sciences Inc. has received notification from Nasdaq that it has regained compliance with the minimum stockholders equity requirement, avoiding immediate delisting.

ENDRA Life Sciences has entered into a definitive merger agreement with Noble Africa LLC, a subsidiary of ASP Isotopes, to create a combined company focused on helium and LNG resources.

ENDRA Life Sciences announced a merger with Noble Africa LLC, a subsidiary of ASP Isotopes, alongside a $50 million private placement.

Endra Life Sciences Inc. announced a $3.8 million private placement offering of common stock and warrants, aiming to bolster working capital.

ENDRA Life Sciences received a delisting notice from Nasdaq due to insufficient stockholders' equity, despite previous compliance efforts.

ENDRA Life Sciences reports a net loss of $1.3 million for Q1 2026 while facing Nasdaq delisting risks due to equity deficiencies.

ENDRA Life Sciences reported reduced net losses and operating expenses for Q3 2025, while initiating a Digital Asset Treasury strategy and addressing Nasdaq listing compliance.

ENDRA Life Sciences reported a significantly reduced net loss in the first half of 2025, while announcing a new, unproven cryptocurrency treasury strategy and ongoing capital needs.

ENDRA Life Sciences reports a reduced net loss for Q1 2025 compared to Q1 2024, as the company focuses on commercializing its TAEUS technology while addressing ongoing financial challenges.

ENDRA Life Sciences has amended its quarterly report for the period ended September 30, 2024, solely to add inline XBRL tagging, while also providing an update on its financial condition and business operations.

ENDRA Life Sciences reported a net loss of $2.35 million for the third quarter of 2024 and is continuing to develop its TAEUS technology while facing financial challenges.

ENDRA Life Sciences reported a net loss of $7.03 million for 2025, faces substantial doubt about its ability to continue as a going concern, and is evaluating strategic alternatives while delaying its key FDA submission.

ENDRA Life Sciences files an amendment to its annual report to correct a typographical error in the auditor's report regarding the date and PCAOB ID number.

ENDRA Life Sciences Inc.'s 10-K filing reveals ongoing financial challenges and operating losses, despite advancements in its TAEUS technology and a strategic shift towards metabolic disease management.

ENDRA Life Sciences Inc. released its 10-K filing, detailing its financial status, ongoing development of its TAEUS technology, and future strategic plans.

ENDRA Life Sciences announced a definitive merger agreement with Noble Africa, aiming to gain exposure to Renergen's Virginia Gas Project and renaming the combined entity Noble Africa Inc.

ASP Isotopes Inc. announced that its subsidiary, Tetra4 Proprietary Limited (a Renergen Limited subsidiary), has entered into a new five-year take-or-pay contract for the sale of liquified natural gas (LNG) from the Virginia Gas Project.

ASP Isotopes Inc. announced its participation in Citi's 2026 Natural Resources Conference, including investor meetings, and provided an update on its proposed merger with ENDRA Life Sciences Inc.

ASP Isotopes Inc. updates shareholders on strong progress in PET Labs and Renergen, with helium production set to commence and significant EBITDA targets projected.

ASPI Isotopes Inc. and ENDRA Life Sciences Inc. have announced plans for a merger, aiming to create a combined entity focused on helium and LNG production.

ASP Isotopes (Noble Africa) details proposed merger with ENDRA Life Sciences, highlighting the critical global helium shortage and the unique Virginia Gas Project.

ENDRA Life Sciences Inc. has filed a definitive proxy statement with the SEC, outlining information required for an upcoming shareholder meeting.

ENDRA Life Sciences Inc. calls for its 2025 Annual Meeting to vote on proposals including a significant increase in authorized shares and officer liability limitations.

ENDRA Life Sciences Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

ENDRA Life Sciences is asking stockholders to approve a reverse stock split proposal, with ratios ranging from 1-for-4 to 1-for-35, to increase its stock price and maintain its Nasdaq listing.

ENDRA Life Sciences is appealing a Nasdaq delisting determination after its stock price fell below $0.10, and is seeking a reverse stock split at its upcoming annual meeting to regain compliance.

ENDRA Life Sciences Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

ENDRA Life Sciences Inc. is launching a public offering of common stock and warrants to raise approximately $95.6 million, primarily to fund a new, untested cryptocurrency treasury strategy while continuing development of its core ultrasound technology.

ENDRA Life Sciences Inc. is launching a public offering of common stock and warrants to raise approximately $118 million, primarily to fund a new treasury strategy focused on holding bitcoin and other cryptocurrencies, while continuing to develop its TAEUS medical technology.

ENDRA Life Sciences Inc. announces a significant strategic shift to allocate the majority of its capital raise proceeds to a cryptocurrency treasury strategy, alongside a renewed focus on its TAEUS technology for metabolic disease management, while addressing ongoing Nasdaq listing compliance issues.

ENDRA Life Sciences is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common stock purchase warrants.

ENDRA Life Sciences launches an offering of common stock and warrants, aiming to raise approximately $4.3 million for working capital and general corporate purposes.

ENDRA Life Sciences is launching a firm commitment public offering of common stock, pre-funded warrants, and accompanying Series A and Series B warrants to raise capital for working capital and general corporate purposes.

ENDRA Life Sciences director Anthony DiGiandomenico has entered into a voting agreement, committing to support a merger with ASP Isotopes Inc. and its subsidiaries.

Anthony DiGiandomenico, a director at ENDRA Life Sciences Inc., has increased his beneficial ownership to 9.99% of the company's common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 3.0% beneficial ownership stake in ENDRA Life Sciences Inc., primarily through warrants.

S.H.N. Financial Investments Ltd. reported a 3.0% beneficial ownership in ENDRA Life Sciences Inc. through Series A Warrants, a significant reduction from a prior common stock holding.

John Carter Lipman has disclosed a 9.99% beneficial ownership stake in ENDRA Life Sciences Inc., primarily for passive investment purposes.

ATW Master Fund V LP and its affiliates have disclosed a 9.9% beneficial ownership stake in ENDRA Life Sciences Inc., totaling 116,024 common shares.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, disclosing a 6.22% beneficial ownership stake in ENDRA Life Sciences Inc. as of December 31, 2024.